## TMO: Thermo Fisher Scientific Inc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.3% below STRENGTH zone (4.0-10.0%); PEG 2.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($545.91)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. 13,224 Shares in Thermo Fisher Scientific Inc. $TMO Bought by Shorepoint Capital Partners LLC**
- Source: MarketBeat | 20251216T123059 | Bullish | Relevance: 100%
- Shorepoint Capital Partners LLC initiated a new position in Thermo Fisher Scientific Inc. ($TMO), purchasing 13,224 shares valued at approximately $6.41 million in Q3, making it their 28th-largest holding. The company reported strong Q3 earnings, beating analyst estimates for EPS and revenue, and announced a $5.00 billion share buyback program and a quarterly dividend of $0.43 per share. Despite significant insider selling over the past three months, institutional ownership of TMO remains high, and analysts maintain a "Moderate Buy" consensus rating for the stock.

**2. MASTERINVEST Kapitalanlage GmbH Makes New $1.15 Million Investment in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251215T120817 | Bullish | Relevance: 100%
- MASTERINVEST Kapitalanlage GmbH recently invested $1.15 million in Thermo Fisher Scientific Inc., acquiring 2,832 shares of the medical research company. This move follows similar investments by other institutional investors and hedge funds, showing strong institutional interest in TMO. Analysts have a "Moderate Buy" rating for the stock with an average target price of $614.60, and insider transactions show some selling activity balanced by a share repurchase program.

**3. National Bank of Canada FI Decreases Stock Holdings in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251215T102458 | Somewhat-Bullish | Relevance: 100%
- National Bank of Canada FI significantly reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 41.6% in the second quarter, now holding 290,100 shares valued at approximately $117.6 million. This move comes as insiders have also been net sellers, disposing of about $86.5 million worth of shares. Despite institutional selling, Thermo Fisher Scientific reported strong quarterly earnings, beating analyst estimates, and announced a $5.0 billion share buyback program, with analysts maintaining a "Moderate Buy" consensus and an average price target of $614.60.

**4. B. Riley Wealth Advisors Inc. Purchases New Shares in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251215T082634 | Somewhat-Bullish | Relevance: 100%
- B. Riley Wealth Advisors Inc. acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by purchasing 5,647 shares valued at approximately $2.29 million during the second quarter. The medical research company recently reported strong quarterly earnings, beating analyst estimates, and authorized a $5.0 billion share repurchase program. Despite significant insider selling over the past three months, institutional investors continue to adjust their positions in TMO.

**5. Capital Asset Advisory Services LLC Grows Stock Position in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251216T102834 | Bullish | Relevance: 100%
- Capital Asset Advisory Services LLC increased its stake in Thermo Fisher Scientific (NYSE:TMO) by 31.8% in Q3, now owning 8,584 shares worth $4.16 million. Despite institutional buying, company insiders have been net sellers, disposing of 149,271 shares totaling approximately $86.5 million in the last 90 days. Thermo Fisher Scientific reported strong Q3 results, provided favorable FY2025 EPS guidance, approved a $5 billion share buyback, and declared a $0.43 quarterly dividend.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $675 | $635 | +6% |
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.12 elevated, pricing in significant growth expectations. Forward P/E 23.1x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (4 raises, avg +11%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $214.2B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.12 |
| Forward P/E | 23.1 |
| Current P/E | 25.1 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.4% to -1.3% (+2.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.3pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.18x) but short-term weakness (below SMA20). MACD histogram bearish (-2.36), momentum weakening. RSI neutral at 48. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.31% (CS: 30) | Neutral |
| RSI_14 | 48.3 | Neutral |
| MACD Histogram | -2.36 | Bearish |
| vs SMA20 | 0.985x | Below |
| vs SMA50 | 1.008x | Above |
| vs SMA200 | 1.182x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $570.33
- **Stop Loss:** $545.91 (4.3% risk)
- **Target:** $594.75 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 40
- **Position Value:** $22,813.20
- **Portfolio %:** 22.81%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*